Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

The ACR and Partners Help Get Legislation Passed in New York to Limit Step Therapy

  |  

What You Can Do
For rheumatologists who want to get more involved in advocating for their patients, Dr. Blumstein emphasizes the importance of attending state society meetings to educate themselves on local issues; he also suggests participating in advocacy efforts and encouraging patients to advocate for themselves on issues that will help preserve their access to care.

The Waiting Begins
As of now, the bill awaits Governor Andrew Cuomo’s signature to make it law. If signed, the law will take effect on Jan. 1, 2017, and New York will join a number of other states that have already enacted laws to limit or prohibit step therapy (e.g., Connecticut, Indiana, Kentucky, Louisiana, Maryland, Mississippi and Washington).

ADVERTISEMENT
SCROLL TO CONTINUE

Mary Beth Nierengarten is a freelance medical journalist based in Minneapolis, Minn.

Related Articles

    N.Y. Rheumatologist Makes Advocacy a Priority

    In 2005, not long after he became a private practice rheumatologist on Long Island, N.Y., Howard Blumstein, MD, dipped his toe into the advocacy pool at the encouragement of his partner, Max Hamburger, MD. “I thought it would be interesting to learn more about the issues that affect our patients and our practices, and I…

    Step Therapy, Biosimilars among ACR’s 2017 State-Level Priorities

    Opportunities and challenges will continue to face the rheumatology community in 2017. In response to these challenges, the ACR has outlined its federal– and state-level legislative and regulatory healthcare priorities for the year. Howard Blumstein, MD, chair of the ACR Affiliate Society Council, says that achieving at least some of these priorities at the state…

    Howard Blumstein, MD, Assumes RheumPAC Chair

    “Advocacy is not about bribery. There’s nothing dirty about advocating for your patients and the future of your profession in terms of workforce, therapeutic advances and the financial viability of our practices. It’s our duty to do this,” he says. In his new role as the RheumPAC chair, he wants to help ACR/ARP members “see how vital these activities are to the success of our profession.”